1 - 25 of 39 results for author:"Dunn B.M." in Literature citations
Results Customize
› Repeat search in UniProtKB (966)
| Structural and biochemical characterization of the inhibitor complexes of xenotropic murine leukemia virus-related virus protease. Li M., Gustchina A., Matuz K., Tozser J., Namwong S., Goldfarb N.E., Dunn B.M., Wlodawer A. FEBS J. 278:4413-4424(2011) · UniProtKB (1) |
| Structure of the unbound form of HIV-1 subtype A protease: comparison with unbound forms of proteases from other HIV subtypes. Robbins A.H., Coman R.M., Bracho-Sanchez E., Fernandez M.A., Gilliland C.T., Li M., Agbandje-McKenna M., Wlodawer A., Dunn B.M., McKenna R. Acta Crystallogr. D Biol. Crystallogr. 66:233-242(2010) · Mapped (1) |
| Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to combination antiretroviral therapy with a protease inhibitor. Ho S.K., Perez E.E., Rose S.L., Coman R.M., Lowe A.C., Hou W., Ma C., Lawrence R.M., Dunn B.M., Sleasman J.W. et al. AIDS 23:1631-1640(2009) · UniProtKB (797) |
| Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis. Liu P., Marzahn M.R., Robbins A.H., Gutierrez-de-Teran H., Rodriguez D., McClung S.H., Stevens S.M. Jr., Yowell C.A., Dame J.B., McKenna R. et al. Biochemistry 48:4086-4099(2009) · Mapped (1) |
| Crystallographic evidence for noncoplanar catalytic aspartic acids in plasmepsin II resides in the Protein Data Bank. Robbins A.H., Dunn B.M., Agbandje-McKenna M., McKenna R. Acta Crystallogr. D Biol. Crystallogr. 65:294-296(2009) · Mapped (1) |
| High-resolution structure of unbound human immunodeficiency virus 1 subtype C protease: implications of flap dynamics and drug resistance. Coman R.M., Robbins A.H., Goodenow M.M., Dunn B.M., McKenna R. Acta Crystallogr. D Biol. Crystallogr. D64:754-763(2008) · Mapped (1) |
| Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation. Clemente J.C., Robbins A., Grana P., Paleo M.R., Correa J.F., Villaverde M.C., Sardina F.J., Govindasamy L., Agbandje-McKenna M., McKenna R. et al. J. Med. Chem. 51:852-860(2008) · UniProtKB (1) |
| The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics of HIV-1 subtype C protease. Coman R.M., Robbins A.H., Fernandez M.A., Gilliland C.T., Sochet A.A., Goodenow M.M., McKenna R., Dunn B.M. Biochemistry 47:731-743(2008) · Mapped (1) |
| Processing, catalytic activity and crystal structures of kumamolisin-As with an engineered active site. Okubo A., Li M., Ashida M., Oyama H., Gustchina A., Oda K., Dunn B.M., Wlodawer A., Nakayama T. FEBS J. 273:2563-2576(2006) · UniProtKB (1) |
| Analysis of HIV-1 CRF_01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Clemente J.C., Coman R.M., Thiaville M.M., Janka L.K., Jeung J.A., Nukoolkarn S., Govindasamy L., Agbandje-McKenna M., McKenna R., Leelamanit W. et al. Biochemistry 45:5468-5477(2006) · Mapped (1) |
| Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor. Clemente J.C., Govindasamy L., Madabushi A., Fisher S.Z., Moose R.E., Yowell C.A., Hidaka K., Kimura T., Hayashi Y., Kiso Y. et al. Acta Crystallogr. D Biol. Crystallogr. 62:246-252(2006) · UniProtKB (1) |
| Crystal structure of human Taspase1, a crucial protease regulating the function of MLL. Khan J.A., Dunn B.M., Tong L. Structure 13:1443-1452(2005) · UniProtKB (1) |
| Catalytic residues and substrate specificity of recombinant human tripeptidyl peptidase I (CLN2). Oyama H., Fujisawa T., Suzuki T., Dunn B.M., Wlodawer A., Oda K. J. Biochem. 138:127-134(2005) · Mapped (10) |
| Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. Clemente J.C., Moose R.E., Hemrajani R., Whitford L.R., Govindasamy L., Reutzel R., McKenna R., Agbandje-McKenna M., Goodenow M.M., Dunn B.M. Biochemistry 43:12141-12151(2004) · UniProtKB (1) |
| IA3, an aspartic proteinase inhibitor from Saccharomyces cerevisiae, is intrinsically unstructured in solution. Green T.B., Ganesh O., Perry K., Smith L., Phylip L.H., Logan T.M., Hagen S.J., Dunn B.M., Edison A.S. Biochemistry 43:4071-4081(2004) · Mapped (2) |
| Two inhibitor molecules bound in the active site of Pseudomonas sedolisin: a model for the bi-product complex following cleavage of a peptide substrate. Wlodawer A., Li M., Gustchina A., Oyama H., Oda K., Beyer B.B., Clemente J., Dunn B.M. Biochem. Biophys. Res. Commun. 314:638-645(2004) · UniProtKB (1) |
| A model of tripeptidyl-peptidase I (CLN2), a ubiquitous and highly conserved member of the sedolisin family of serine-carboxyl peptidases. Wlodawer A., Durell S.R., Li M., Oyama H., Oda K., Dunn B.M. BMC Struct. Biol. 3:8-8(2003) · Mapped (6) |
| The 1.4 a crystal structure of kumamolysin: a thermostable serine-carboxyl-type proteinase. Comellas-Bigler M., Fuentes-Prior P., Maskos K., Huber R., Oyama H., Uchida K., Dunn B.M., Oda K., Bode W. Structure 10:865-876(2002) · UniProtKB (1) |
| A CLN2-related and thermostable serine-carboxyl proteinase, kumamolysin: cloning, expression, and identification of catalytic serine residue. Oyama H., Hamada T., Ogasawara S., Uchida K., Murao S., Beyer B.B., Dunn B.M., Oda K. J. Biochem. 131:757-765(2002) · UniProtKB (1) |
| Retroviral proteases. Dunn B.M., Goodenow M.M., Gustchina A., Wlodawer A. Genome Biol. 3:REVIEWS3006.1-REVIEWS3006.7(2002) · UniProtKB (28) |
| Inhibitor complexes of the Pseudomonas serine-carboxyl proteinase. Wlodawer A., Li M., Gustchina A., Dauter Z., Uchida K., Oyama H., Goldfarb N.E., Dunn B.M., Oda K. Biochemistry 40:15602-15611(2001) · UniProtKB (1) |
| Carboxyl proteinase from Pseudomonas defines a novel family of subtilisin-like enzymes. Wlodawer A., Li M., Dauter Z., Gustchina A., Uchida K., Oyama H., Dunn B.M., Oda K. Nat. Struct. Biol. 8:442-446(2001) · UniProtKB (1) |
| Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. Perez E.E., Rose S.L., Peyser B., Lamers S.L., Burkhardt B., Dunn B.M., Hutson A.D., Sleasman J.W., Goodenow M.M. J. Infect. Dis. 183:579-588(2001) · UniProtKB (38) |
| The potency and specificity of the interaction between the IA3 inhibitor and its target aspartic proteinase from Saccharomyces cerevisiae. Phylip L.H., Lees W.E., Brownsey B.G., Bur D., Dunn B.M., Winther J.R., Gustchina A., Li M., Copeland T., Wlodawer A. et al. J. Biol. Chem. 276:2023-2030(2001) · Mapped (2) |
| Structural basis for the inhibition of porcine pepsin by Ascaris pepsin inhibitor-3. Ng K.K., Petersen J.F., Cherney M.M., Garen C., Zalatoris J.J., Rao-Naik C., Dunn B.M., Martzen M.R., Peanasky R.J., James M.N. Nat. Struct. Biol. 7:653-657(2000) · UniProtKB (1) · Mapped (1) |